Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Ultibro Breezhaler Indacaterol/glycopyrronium Chronic obstructive pulmonary disease List with criteria/condition Complete
Ultomiris ravulizumab Neuromyelitis optica spectrum disorder (NMOSD) Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab Atypical hemolytic uremic syndrome Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Ultomiris ravulizumab AChR antibody-positive generalized Myasthenia Gravis Do not reimburse Complete
Ultomiris ravulizumab Generalized Myasthenia Gravis Active
Unituxin dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Complete
Unituxin Dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Complete
Uplizna inebilizumab Neuromyelitis optica spectrum disorders (NMOSD) Reimburse with clinical criteria and/or conditions Complete
Uptravi Selexipag Pulmonary arterial hypertension (WHO class II and III) Reimburse with clinical criteria and/or conditions Complete